OncoResponse Inc.

After the year’s slow start, venture capital fundraising by drug developers has gotten a big boost in recent months, especially in May when two companies raised more than $700m between them – $300m fo

The first half of 2022 saw the NASDAQ Biotechnology Index lose a quarter of its value. Despite a tentative recovery since then, the IPO window is barely ajar and valuations remain well below the highs

To hear OncoResponse Inc . CEO Clifford Stocks tell it, his company is “approaching that interesting time point where pharma likes to partner” as it readies lead candidate OR2805 for efficacy studies

Biopharmaceutical companies raised $1.5bn in 11 venture capital mega-rounds of $100m or more during the last week and a half of March. Including VC and other financings under $100m, 35 privately held